Theratechnologies Inc (TSE:TH)‘s stock had its “sector perform market weight” rating reiterated by stock analysts at National Bank Financial in a report issued on Tuesday.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity reduced their price objective on Theratechnologies from C$4.25 to C$3.75 in a research note on Thursday, July 7th. Mackie reduced their price objective on Theratechnologies from C$5.30 to C$4.40 in a research note on Wednesday, July 6th.

Shares of Theratechnologies (TSE:TH) traded up 4.63% during midday trading on Tuesday, reaching $2.94. 62,118 shares of the company were exchanged. The company has a 50 day moving average price of $2.65 and a 200-day moving average price of $2.48. Theratechnologies has a 12-month low of $1.26 and a 12-month high of $3.74. The stock has a market capitalization of $193.84 million and a P/E ratio of 735.00.

About Theratechnologies

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company’s product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Receive News & Stock Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related stocks with our FREE daily email newsletter.